B-screen
B-Screen Platform
The B-Screen platform is a technological infrastructure dedicated to the discovery and functional characterization of antibodies and immune receptors derived from B and T lymphocytes from patient samples. It enables the identification of therapeutic target–antibody pairs of interest through high-throughput single-cell screening approaches performed in a physiologically relevant context.
Designed for both academic teams and industrial partners, B-Screen provides integrated access to cutting-edge technologies, from immune repertoire analysis to the functional validation of identified antibodies and receptors.
Légende de l’image à remplacer
B-Screen supports immunology and antibody development projects throughout the key stages of the discovery phase. The platform notably addresses the following needs:
- Identify novel antibodies and receptors (BCRs, TCRs) from patient-derived cells
- Explore immune repertoires across various pathological contexts
- Characterize antibody specificity, affinity, and biological functions
- Discover novel therapeutic targets and their associated ligands
- Generate proof-of-concept data for antibody-based approaches
- Accelerate the “bed-to-bench” transition through the direct exploitation of clinical samples
B-screen
Our Technology
B-Screen relies on an integrated approach combining single-cell screening, microfluidics, functional immunology, and multi-omics analyses. This strategy is powered by the Beacon technology, which enables the manipulation and analysis of individual living cells with extremely high precision.
Concretely, immune cells of interest — mainly B and T cells — are isolated from patient blood samples and introduced into a microfluidic chip. The Beacon platform uses optoelectronic fields to capture and position each individual cell into micro-compartments called “NanoPens”.
At this stage, each cell is analyzed under near-physiological conditions. The technology makes it possible to monitor antibody secretion in real time, assess specificity, and measure functional activity. Unlike conventional approaches, these analyses are performed at the single-cell level, without dilution or loss of information.
Cells displaying the most relevant profiles are then automatically selected. Their genetic material is recovered to identify antibody sequences, which can subsequently be produced and further characterized through multi-omics analyses (genomics, transcriptomics, proteomics).
Beacon technology therefore constitutes the core of the B-Screen platform: it directly connects functional immune cell data to clinical applications, moving from patient-derived samples toward innovative therapeutic solutions.
Key Features
The B-Screen platform offers a comprehensive range of services dedicated to antibody and therapeutic target discovery.
High-throughput single-cell screening
• Analysis of individual B and T cells
• Identification of autoreactive or target-specific antibodies
• Use of BEACON™ microfluidic technologies
Access to clinical samples
• Exploitation of patient-derived B and T cells
• “Bed-to-bench” translational approach
Advanced functional analysis
• Antigen specificity, affinity, and biological function assays
• Cross-reactivity and mechanism-of-action studies
Target and antibody discovery
• Identification of novel target–antibody pairs
Production and reformatting
• Cloning and production of antibodies and receptors
• Adaptation into different therapeutic formats
Integration into a translational workflow
• Generation of proof-of-concept data
• Interface with downstream platforms (Cell-Scale, CROs)
• Acceleration of preclinical development
Les membres de l'équipe
Noella Lopes Pappalardo
Project manager for technological and scientific plateforms at uar mibtech
Daniel Olive
MIB medical scientific and technical manager
Actualités